128 related articles for article (PubMed ID: 35475716)
21. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.
Cui JY; Zhou RR; Han S; Wang TS; Wang LQ; Xie XH
J Clin Pharm Ther; 2018 Aug; 43(4):556-570. PubMed ID: 29733433
[TBL] [Abstract][Full Text] [Related]
22. Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis.
Cai R; Yuan Y; Sun J; Xia W; Huang R; Tian S; Dong X; Shen Y; Wang S
Expert Opin Pharmacother; 2016 Oct; 17(14):1839-49. PubMed ID: 27488607
[TBL] [Abstract][Full Text] [Related]
23. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
24. Statin Therapy Among Bariatric Patients: The Impact on Metabolic Outcomes and Diabetes Status.
Mendonça FM; Silva MM; Borges-Canha M; Neves JS; Costa C; Cabral PM; Guerreiro V; Lourenço R; Meira P; Ferreira MJ; Salazar D; Pedro J; Varela A; Souto S; Lau E; Freitas P; Carvalho D; Group C
Exp Clin Endocrinol Diabetes; 2022 Aug; 130(8):539-545. PubMed ID: 35320845
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of Medical Nutritional Therapy in the Management of Type 2 Diabetes Mellitus.
Varadaraj G; Sangeetha B; Nithiya DR; Dixit PK
J Assoc Physicians India; 2021 Apr; 69(4):11-12. PubMed ID: 34470186
[TBL] [Abstract][Full Text] [Related]
26. Diabetes Self-Management Education and Medical Nutrition Therapy: A Multisite Study Documenting the Efficacy of Registered Dietitian Nutritionist Interventions in the Management of Glycemic Control and Diabetic Dyslipidemia through Retrospective Chart Review.
Marincic PZ; Salazar MV; Hardin A; Scott S; Fan SX; Gaillard PR; Wyatt C; Watson L; Green P; Glover P; Hand M
J Acad Nutr Diet; 2019 Mar; 119(3):449-463. PubMed ID: 30219311
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
Cusi K; Cunningham GR; Comstock JP
Diabetes Care; 1995 Jun; 18(6):843-51. PubMed ID: 7555511
[TBL] [Abstract][Full Text] [Related]
28. Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.
Gómez-Sámano MÁ; Baquerizo-Burgos JE; Coronel MFC; Wong-Campoverde BD; Villanueva-Martinez F; Molina-Botello D; Avila-Rojo JA; Palacios-Báez L; Cuevas-Ramos D; Gomez-Perez FJ; Zentella-Dehesa A; Aguayo-González Á; Gulias-Herrero A
BMC Endocr Disord; 2018 Nov; 18(1):77. PubMed ID: 30390651
[TBL] [Abstract][Full Text] [Related]
29. Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins.
Rajanna V; Campbell KB; Leimberger J; Mohanty BD; Guyton JR
J Clin Lipidol; 2012; 6(2):168-73. PubMed ID: 22385550
[TBL] [Abstract][Full Text] [Related]
30. Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative.
De Cosmo S; Viazzi F; Pacilli A; Giorda C; Ceriello A; Gentile S; Russo G; Rossi MC; Nicolucci A; Guida P; Di Bartolo P; Pontremoli R;
Nephrol Dial Transplant; 2015 Sep; 30(9):1526-33. PubMed ID: 25883195
[TBL] [Abstract][Full Text] [Related]
31. Pitavastatin: clinical effects from the LIVES Study.
Teramoto T
Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
[TBL] [Abstract][Full Text] [Related]
32. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
33. The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription.
Ellis M; Krashin E; Hamburger-Avnery O; Gan S; Elis A; Ashur-Fabian O
Leuk Lymphoma; 2017 May; 58(5):1172-1177. PubMed ID: 27650030
[TBL] [Abstract][Full Text] [Related]
34. Current status of low-density lipoprotein cholesterol for primary prevention of coronary artery disease in late-stage elderly persons with type 2 diabetes mellitus: A retrospective, single-center study.
Yamamoto Y; Ito J; Ito K; Fujii M; Nakajima R; Saito K; Yagyu H
J Diabetes Investig; 2022 Sep; 13(9):1567-1576. PubMed ID: 35510958
[TBL] [Abstract][Full Text] [Related]
35. Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes.
Bashier AM; Abdelgadir EI; Khalifa AA; Rashid F; Abuelkeir SM; Bachet FE
Saudi Med J; 2014 Nov; 35(11):1404-7. PubMed ID: 25399222
[TBL] [Abstract][Full Text] [Related]
36. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
[TBL] [Abstract][Full Text] [Related]
38. Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study.
Itoh H; Komuro I; Takeuchi M; Akasaka T; Daida H; Egashira Y; Fujita H; Higaki J; Hirata KI; Ishibashi S; Isshiki T; Ito S; Kashiwagi A; Kato S; Kitagawa K; Kitakaze M; Kitazono T; Kurabayashi M; Miyauchi K; Murakami T; Murohara T; Node K; Ogawa S; Saito Y; Seino Y; Shigeeda T; Shindo S; Sugawara M; Sugiyama S; Terauchi Y; Tsutsui H; Ueshima K; Utsunomiya K; Yamagishi M; Yamazaki T; Yo S; Yokote K; Yoshida K; Yoshimura M; Yoshimura N; Nakao K; Nagai R;
Diabetes Obes Metab; 2019 Apr; 21(4):791-800. PubMed ID: 30393955
[TBL] [Abstract][Full Text] [Related]
39. The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Weiss R; Harder M; Rowe J
Clin Ther; 2003 May; 25(5):1490-7. PubMed ID: 12867223
[TBL] [Abstract][Full Text] [Related]
40. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria.
Davidson MB; Schriger DL; Peters AL; Lorber B
JAMA; 1999 Apr; 281(13):1203-10. PubMed ID: 10199430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
